Korean obesity drug developers Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
02:13
Feb 04
Feb 04
Korean obesity drugs benefit from competition.
Novo Nordisk's guidance cut due to obesity-drug competition is not bad for Korean obesity-drug developers; it signals a larger market where domestic candidates such as Samchundang Pharm can benefit.
MED
About Korean obesity drug developers Investor Commentary
Across the available history and selected sources, Buzzberg tracks Korean obesity drug developers across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Jang Woo-jin.